Theorem Clinical Research

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Evotec takes legal steps against Andromeda Biotech

Friday, September 19, 2014 01:26 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, will take legal steps against Israel-based Andromeda Biotech to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277.

More... »


Cancer Research U.K., Cancer Research Technology, Asterias Biotherapeutics partner

Friday, September 19, 2014 12:51 PM

Cancer Research U.K. and Cancer Research Technology (CRT), the charity's development and commercialization arm, have reached an agreement with Asterias Biotherapeutics, a California-based biotechnology company focused on regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.

More... »


ABPI comments on NICE’s response to value-based assessment consultation

Friday, September 19, 2014 12:50 PM

The National Institute for Health and Care Excellence (NICE) board has considered proposals on value-based assessment (VBA) following a three-month consultation.

More... »

Sigma-Aldrich, University of Michigan Medical School partner

Friday, September 19, 2014 12:45 PM

Sigma-Aldrich (SIAL), a St. Louis, Mo.-based life science and high technology company, has entered into a new gene editing partnership with the University of Michigan (U-M) Medical School's Vector Core. Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation and dedicated gene editing bioinformaticians.

More... »

Delphinus appoints Mark J. Forchette president and CEO

Thursday, September 18, 2014 02:36 PM

Delphinus Medical Technologies, a Michigan developer of SoftVue, a whole breast ultrasound system that incorporates a ring transducer design, has named Mark J. Forchette president and CEO.

More... »

FDA approves STENDRA for ED

Thursday, September 18, 2014 02:21 PM

The FDA has approved a supplemental new drug application (sNDA) for Vivus’ STENDRA (avanafil). STENDRA now is the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.

More... »

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »

Sanofi, MyoKardia collaborate on genetic heart disease

Thursday, September 18, 2014 01:38 PM

Sanofi and MyoKardia, a South San Francisco-based, privately held company developing precision therapies for genetic heart disease, are collaborating to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia's pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction.

More... »

Sutro Biopharma, EMD Serono partner on antibody drug conjugates

Thursday, September 18, 2014 01:37 PM

Sutro Biopharma, a California-based biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and EMD Serono, the biopharmaceutical division of Merck, have inked a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

More... »

Bayer plans to focus entirely on life science businesses

Thursday, September 18, 2014 01:27 PM

Bayer has announced that it intends, in the future, to focus entirely on its life science businesses—HealthCare and CropScience—and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a human, animal and plant health company. The supervisory board unanimously has approved the board of management's plans.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs